Preventive treatment using laser of age-related macular degeneration of the contralateral eye after age-related macular degeneration of the first eye]

Since 1982, and with informed patient consent, we have photocoagulated confluent drusen and limited serous pigment epithelium detachment (SPED) in the fellow eye of ten patients suffering from advanced, disciform type, age-related macula degeneration (ARMD). This treatment was only carried out on appearance of metamorphopsia. Photocoagulation was performed with either the green ray of the argon laser, or the yellow ray of a dye laser. Spots of about 200 microns were placed in a grid-like fashion among the drusen. No complications were observed due to the treatment. The follow-up period on these ten patients, eight women and two men, mean age 77 years, was two to eight years, and the three patients have died. The drusen disappeared completely in three patients and partially in one. The functional results seemed favorable in three cases. In one case of confluent drusen associated with SPED and serous retinal detachment, vision improved remarkably from 0.3 to 0.5 with a Parinaud 2, with a follow-up of five years. In another case, the improvement was from 0.4 to 0.7 but the patient died after only a few months. In another case, vision has been stable for five years. The vision of the seven remaining patients deteriorated; three cases showed central areolar sclerosis, and one case a localised new vessel with vision less than 0.1. In three cases vision dropped to 0.2 and Parinaud 6, but they have been stable for at least four years (eight years for one patient).(ABSTRACT TRUNCATED AT 250 WORDS)     

ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography

PURPOSE: To evaluate the efficacy of indocyanine green angiography (ICGA)-guided laser photocoagulation in eyes with fluorescein angiographic evidence of occult choroidal neovascularization (O-CNV) in patients with age-related macular degeneration (ARMD) with or without pigment epithelium detachment (PED). METHODS: Eighty eyes of 79 consecutive patients with O-CNV underwent laser treatment of a clearly outlined extrafoveal ICGA hyperfluorescent area, presumed to be focal CNV. Four types of presumed CNV were treated: Group 1 (20 eyes), CNV beneath the PED; Group 2 (23 eyes), CNV at the margin of the PED; Group 3 (10 eyes), parapapillary CNV and PED; and Group 4 (27 eyes), macular CNV without PED. Median follow-up was 17.5 months (range, 6-24 months). RESULTS: After 1 year, 15% of the eyes in Group 1, 30% in Group 2, 100% in Group 3, and 52% in Group 4 had obliteration of the presumed CNV. After 1 year, visual acuity was stable or improved in 18% of Group 1, in 37.5% of Group 2, in 100% of Group 3, and in 73% of Group 4. The remaining eyes worsened. CONCLUSIONS: Indocyanine green angiography-guided laser treatment may improve or stabilize visual acuity in some eyes with O-CNV. The best outcome is seen in eyes with presumed parapapillary CNV, probably made up of choroidal telangiectases in many cases. The type and location of the presumed CNV influence prognosis after laser treatment considerably. A randomized, controlled clinical study appears necessary to investigate the efficacy of ICGA-guided laser treatment in different types of presumed CNV. The inclusion criteria for further trials need to be defined with precision, as data from patients with different choroidal vascular abnormalities have been pooled until now.     

Argon laser vs. subthreshold infrared (810-nm) diode laser macular grid photocoagulation in nonexudative age-related macular degeneration

BACKGROUND: A diode laser can be used to create a subthreshold (invisible end point) lesion in patients with age-related macular degeneration (AMD). This has the potential benefit of localizing the treatment effect to the retinal pigment epithelium and sparing more of the overlying sensory retina. We performed a study to compare the safety and efficacy of argon laser and subthreshold infrared (810-nm) diode laser macular grid photocoagulation in reducing the number of drusen in patients with AMD. METHODS: We reviewed the charts of 144 patients with bilateral early-stage nonexudative AMD, characterized by soft drusen. One eye of each patient was treated, and the other eye served as a control. Seventy-eight eyes of 78 patients with a mean age of 67.5 (standard deviation [SD] 8.3) years underwent argon laser macular grid photocoagulation at a university-affiliated hospital in Bologna, Italy, and 66 eyes of 66 patients with a mean age of 66.4 (SD 6.3) years underwent subthreshold infrared (810-nm) diode laser macular grid photocoagulation at a private clinic in Bologna. Each group was classified into three subgroups based on the number of drusen (more than 20, 10 to 20, or less than 10). The patients underwent fluorescein angiography, fundus examination, measurement of far (Snellen chart) and near (Jaeger chart) best corrected visual acuity, and visual field and contrast sensitivity testing. The mean length of follow-up was 18 (SD 0.5) months. RESULTS: At 18 months, far and near best corrected visual acuity were statistically significantly improved in the treatment groups compared with the untreated group (p < 0.001, Mann-Whitney U test). There was no significant difference in visual acuity between the treatment groups. Compared with baseline, the number of drusen was significantly reduced in both treatment groups (p < 0.001). Evolution of the disease was observed in the untreated group. The visual field was slightly but significantly reduced after argon laser treatment (p < 0.001) but not diode laser treatment; the difference in visual field between the two groups was not significant. There was a slight reduction in contrast sensitivity, particularly with night vision, after argon laser treatment but not diode laser treatment. The difference between the two treatment groups was significant (p < 0.01). INTERPRETATION: Subthreshold infrared diode macular grid photocoagulation may be a safe and viable method for preventing progression of nonexudative AMD.     

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

Purpose

To evaluate the changes in the best-corrected visual acuity (BCVA) after 1 year and after ≥5 years after macular translocation for age-related macular degeneration (AMD) or myopic choroidal neovascularisation (mCNV).

Methods

The medical records of 61 consecutive patients who underwent macular translocation with 360° retinotomy for AMD (35 eyes) or mCNV (26 eyes) were reviewed. Overall, 40 patients, 17 mCNV and 23 AMD, were followed for at least 5 years. BCVA and area of the Goldmann visual field (VF) measured before, 12 months after surgery, and at the final visit.

Results

In the 23 AMD eyes followed for ≥5 years, the mean preoperative BCVA was 1.149±0.105 logMAR units, which significantly improved to 0.69±0.06 logMAR units at 1 year (P<0.001). This BCVA was maintained at 0.633±0.083 logMAR units on their final examination. In the 17 eyes with mCNV followed for ≥5 years, the mean preoperative BCVA was 1.083±0.119 logMAR units, which was significantly improved to 0.689±0.121 logMAR units at 1 year (P=0.001). This BCVA was maintained at 0.678±0.142 logMAR units on their final examination. The area of the VF was significantly decreased at 12 months and did not change significantly thereafter.

Conclusions

Our results show that macular translocation surgery significantly improves the BCVA and significantly decreases the VF area of eyes with mCNV or AMD after first 1 year. The BCVA and VF area do not change significantly from the values at 1 year for at least 5 years.     

Current treatment of age-related macular degeneration.

PURPOSE: To review proved and experimental treatments for exudative and nonexudative complications of age-related macular degeneration (AMD), to consider the impact of current therapy on the structure of future clinical trials, and to consider the role of improved diagnostic imaging techniques on the effectiveness of current therapy as well as the structure of future clinical trials in AMD patients. RESULTS: Defining the cell biology of choroidal new vessel (CNV) formation and geographic atrophy will lead to identification of different biochemical pathways that are the target of AMD treatment. Many treatments and treatment combinations are under study for AMD, but all work through a finite number of pathways. Currently, the most effective proved therapy for AMD-associated CNVs is administered by repeated intravitreal injection of agents that inhibit vascular endothelial growth factor, e.g., ranibizumab. Improved drug delivery will enhance patient satisfaction and possibly will enhance the effectiveness and reduce the risk of current pharmacotherapy for AMD-associated CNVs. Combination therapy (e.g., verteporfin-photodynamic therapy + ranibizumab) appears to reduce the risk and enhance the effectiveness of CNV treatment compared with monotherapy with currently available agents. Improved noninvasive diagnostic imaging may lead to better visual outcomes with existing therapeutic modalities. Improved imaging also may alter favorably the design of future clinical trials for AMD-associated CNVs and thus reduce cost and increase the diversity of sight-saving treatments. CONCLUSIONS: Delineation of the biochemical basis for CNV formation has led to development of pathway-based pharmacotherapy for AMD patients. Areas of investigation that will advance the field further include combination therapy, improved drug delivery, and improved noninvasive, high-resolution diagnostic imaging. The logistics of future clinical trials will be complicated by the need for an active treatment control group, more stringent definition of successful treatment, and the increased numbers of patients required for combination therapy studies.     

年龄相关性黄斑变性视力损害及康复的研究现状

年龄相关性黄斑变性（AMD）是老年人视力丧失的主要原因,分为干性AMD和湿性AMD两大类,干性AMD可以转化为湿性AMD导致视力进一步损害。眼科医生除给予常规治疗外,还应根据患者视力损害的特点加以个性化康复,通过寻找训练优选的视网膜定位点、合理利用各种助视器、恰当的医患沟通、必要的人文关怀及随访来达到有效的视功能康复。     

Early angiographic changes after laser treatment of choroidal neovascularisation in age-related macular degeneration

PURPOSE: To describe angiographic features detectable on fluorescein angiography (FA) and indocyanine green angiography (ICGA) early after laser photocoagulation of choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). METHODS: Thirty-five eyes of patients with AMD and juxtafoveal or extrafoveal CNV referred to the angiographic centre of the Eye Clinic of Trieste were considered. Ophthalmological assessment included FA and ICGA performed 2 days before and 30 min after laser treatment, and then 1, 2, 7, 14, 21 and 28 days after photocoagulation. Further clinical angiographic examinations were carried out 2, 3, 4 and 6 months after treatment. Photocoagulation was performed for classic CNV on FA and occult CNV on FA, appearing as well-defined focal spot on ICGA. RESULTS: Our results show that interpretation of early post-treatment angiographic examinations may be awkward because diffuse leakage on FA and hot spots on ICGA are normally detectable soon after laser treatment and thereafter during the first 2 weeks. Later, at the 3-week control, leakage on FA and hot spots on ICGA are visible in 62.8% and in 37% of cases respectively; they disappear completely by the 4-week control. CONCLUSION: Difficulty in analysing FA and ICGA in the early post-photocoagulation period underlines the importance of the decision regarding when to perform the first reliable post-laser control and how to improve its interpretation. We suggest that the first angiographic control be performed 3 weeks after treatment, strictly monitoring those eyes showing leakage or marginal hot spots over the following weeks. Overlapping the post-laser hypofluorescent area on the pre-laser lesion can ensure the complete coverage of CNV, and analysis of the retinal and choroidal vascular pattern inside and near the photocoagulated area during the different angiographic phases, albeit difficult, is essential for the interpretation of the angiographic lesions.     

Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration

PURPOSE: To determine the predictors of drusen reduction in eyes with nonexudative age-related macular degeneration (ARMD) treated with subthreshold infrared (810 nm) diode laser macular grid photocoagulation. Additionally, to determine the relationship of laser-induced drusen reduction and best-corrected visual acuity (BCVA) 18 months after laser treatment.DESIGN: Randomized controlled clinical trial.METHODS: Fifty patients (100 eyes) with bilateral nonexudative ARMD were enrolled at two centers. One eye of each patient was randomized to the observation; the other eye was treated with 48 subthreshold (invisible end point) applications of infrared (810 nm) diode laser in a macular grid pattern. The eyes that received subthreshold laser treatment were compared with the eyes that received no treatment. The baseline fundus characteristics (number, size, and distribution of drusen, as well as focal hyperpigmentation) from two macula areas (central 1500 micro diameter, pericentral 1500 micro ring area) on stereo color photographs, the number of laser-induced lesions, and the area of laser induced retinal pigment epithelial (RPE) lesions on fluorescein angiography 3 months after treatment were studied as predictors of major drusen reduction (> or = 50% drusen reduction from baseline) 18 months after laser treatment. BCVA at baseline and 18 months later was compared in observation eyes and in laser-treated eyes.RESULTS: Eighteen months after randomization, 24 (48%) of 50 eyes treated with subthreshold laser had major drusen reduction compared with three (6%) of 50 observation eyes (P =.00001). At 3 months post-treatment in laser-treated eyes with major drusen reduction, the mean number of laser-induced lesions on fluorescein angiography was 30.7 and the mean area of RPE change was 0.81 mm(2) compared with 14.8 laser-induced lesions and 0.35 mm(2) area of RPE change in eyes without major drusen reduction (P =.0001 and P =.0003, respectively). At baseline, fundus characteristics were not significantly different between observation eyes and laser-treated eyes or between the major drusen reduction group and the nonmajor drusen reduction group. At 18 months after treatment, BCVA was not significantly different in laser-treated eyes and in observation eyes.CONCLUSIONS: Subthreshold infrared (810 nm) diode laser macular grid photocoagulation in eyes with nonexudative ARMD significantly reduced drusen 18 months after laser treatment. Both the number of subthreshold laser lesions and the area of RPE changes visible on fluorescein angiography 3 months after treatment appeared to be predictors for major drusen reduction 18 months after treatment. However, it remains to be determined whether laser-induced drusen reduction is beneficial for visual acuity or reduces the incidence of choroidal neovascularization (CNV) in eyes with nonexudative ARMD.     

Visual acuity and fixation characteristics in age-related macular degeneration.

PURPOSE: To compare "single letter" (SL) acuity, "crowded letter" (CL) acuity, and "repeated letter" (RL) acuity for patients with age-related macular degeneration (AMD) and investigate if differences between these visual acuities are associated with fixation characteristics. METHODS: A total of 243 patients with AMD had their best-corrected visual acuity measured on an ETDRS chart. SL, CL, and RL acuities were measured using Landolt C targets on a monitor. Fifty-degree-field red-free fundus photographs were taken and a static target was used to calculate the Preferred Retinal Locus (PRL) distance and direction from the fovea. Quality of fixation (consistency and oculomotor response) was also assessed using a fundus camera and a dynamic target. RESULTS: RL acuity was almost always better than CL acuity and SL acuity was almost always better than CL acuity. The mean (+/-SD) RL-CL and SL-CL acuity differences were -0.13 (+/-0.15) logMAR and -0.11 (+/-0.13) logMAR respectively. The median PRL distance was 3.73 degrees and the preferred retinal areas for the location of the PRL were the left (left quadrant of visual field; 39.5% of cases) and superior (inferior quadrant of visual field; 25.4%). Visual acuity was significantly associated with PRL distance but PRL distance only explained 10% of the variation in visual acuity. PRL distance was found to be a significant but weak predictor of the SL-CL acuity difference but fixation quality was not a good predictor of the RL-CL acuity difference. CONCLUSIONS: Although the acuity measured under different stimulus conditions varies, the absolute differences are small. This suggests that these techniques would not be helpful in determining fixation characteristics, or predicting the outcome of rehabilitation in individual patients with AMD.     

Laser photocoagulation as treatment of non-exudative age-related macular degeneration: state-of-the-art and future perspectives

Graefe's Archive for Clinical and Experimental Ophthalmology - To give an updated review of laser approaches to non-exudative age-related macular degeneration (AMD). PubMed and Medline database...     

Sequential combined therapy for treatment of choroidal neovascularization in age-related macular degeneration: photodynamic therapy and thermal laser photocoagulation

PURPOSE: To analyze the results achieved after treating extrafoveal choroidal neovascularization (CNV) recurrences with thermal laser photocoagulation (TLP) in patients who had previously undergone photodynamic therapy (PDT). PATIENTS AND METHODS: Seven eyes (seven patients: four women and three men) that had been initially treated by PDT for CNV associated with age-related macular degeneration (ARMD) and then developed extrafoveal recurrences were treated with green argon TLP. All patients underwent a complete ophthalmologic evaluation and fluorescein angiography. Mean age was 74.4 +/- 4.4 years (range, 69 to 81 years). Five right eyes and two left eyes were treated. Mean follow-up after the beginning of the treatment with PDT was 18.0 +/- 3.5 months (range, 11 to 22 months). Follow-up after TLP was 6.8 +/- 1.0 months (range, 6 to 8 months). RESULTS: Mean best-corrected visual acuity (BCVA) before treatment was 20/150 (range 20/400 to 20/40). After PDT it was 20/281 (range, 20/400 to 20/80), with a mean of 3.1 +/- 0.8 treatments (range, 2 to 4). After TLP, BCVA was 20/233 (range, 20/400 to 20/80), with no statistically significant difference from BCVA after PDT (p = 0.06, Student's t-test paired data). In all cases total closure of CNV was achieved after only one session of TLP. CONCLUSIONS: TLP could be helpful in association with multiple sessions of PDT in order to achieve a complete closure of subfoveal CNV secondary to ARMD. Further studies are required to confirm our findings.     

Utility of indocyanine green angiography guided laser photocoagulation of choroidal neovascularization in age-related macular degeneration

PURPOSE: The efficacy of photocoagulating choroidal neovascularization (CNV) of age-related macular degeneration with indocyanine green angiography(ICG) was evaluated. 1. The utility of ICG-guided laser photocoagulation for juxtafoveal and extrafoveal CNV, 2. The utility of photocoagulating feeder vessels of subfoveal CNV. METHODS: 1. We compared 139 eyes undergoing ICG-guided laser photocoagulation (IA group), with 85 eyes treated with fluorescein angiography (FAG)-guided laser photocoagulation(FA group), of juxtafoveal and extrafoveal CNV. 2. We treated 35 eyes of 35 patients in which feeder vessels detected by ICG served as targets of photocoagulation. RESULTS: 1. The success rate of laser photocoagulation was 81% in the IA group and 82% in the FA group. There was no statically significant difference between the IA and FA groups in terms of distance from the fovea, CNV size, or lesion type. The rates of maintained or improved visual acuity in groups of IA and FA at the final follow-up as compared with those before treatment, were 71% (61/86 eyes) and 65% (36/55 eyes), respectively. 2. The feeder vessels were obliterated in 66%. The percentage of eyes with maintained or improved visual acuity at six months and at final follow-up as compared to visual acuity before treatment was 64% and 58%, respectively. Thirteen(81%) of 16 eyes which had shown extrafoveal feeder vessel ingrowth sites and small CNV of 1-disc area or less showed feeder vessel closure. CONCLUSION: 1. ICG-guided laser photocoagulation of juxtafoveal and extrafoveal CNV should be performed actively in the same way as FAG-guided laser photocoagulation. 2. It is best to attempt to coagulate feeder vessels when they are extrafoveal and when the CNV is small.     

Treatment according to "evidence-based medicine" of aged-related exudative age-related macular degeneration (laser photocoagulation and photodynamic therapy)]

INTRODUCTION: Age related macular degeneration (AMD) is actually the leading cause of severe visual acuity loss in people over 65 in the Western World. Most of the visual loss is due to choroidal neovascularization (CNV). METHODS: Review of the literature. RESULTS: For more then 10 years laser photocoagulation was the only proven treatment for selected cases of AMD according to the evidence based medicine criteria. In 1999 photodynamic therapy was proven to be efficient for the treatment of predominantly classic subfoveal CNV. CONCLUSION: Laser photocoagulation and photodynamic therapy constitute therefore the only evidence based medicine treatment available for CNV in AMD.     

年龄相关性黄斑变性患者玻璃体内注射bevacizumab期间的视功能变化

目的 观察湿性年龄相关性黄斑变性(age-related macular degeneration,AMD)患者在接受玻璃体内注射bevacizumab治疗期间的视功能变化.方法 对18例(21眼)经荧光素眼底血管造影、光学相干断层扫描检查确诊存在黄斑中心凹下脉络膜新生血管的AMD患者行玻璃体内注射bevacizumab,每6周注射1次,每次剂量为1.25mg(0.05 mL),共3次.研究治疗期间患者的EDTRS视力得分、闪光视网膜电图的a、b波振幅值、对比敏感度及视野平均视敏度的变化情况.结果 患者的平均视力EDTRS得分提高,第3次注射后第3天较第1次注射前1 d平均得分提高5.1分(P=0.001);3次注射前1 d,闪光视网膜电图中a、b波振幅值分别为(160.00±47.63)μV、(263.84±65.81)μV;(159.79±55.07)μV、(273.47±92.56)μV;(164.05±57.94)μV、(282.26±96.55)μV;后2次注射前1 d数据与第1次相比,差异无统计学意义(P>0.05);对比敏感度及视野平均视敏感度无明显变化.结论 湿性AMD患者在接受玻璃体内注射bevacizumab后,治疗期间各项视功能指标稳定,多次注射后EDTRS视力得分有所提高.     

One-year results after radiotherapy of choroidal neovascularization in age-related macular degeneration

Summary Choroidal neovascularization (CNV) associated with age-related macular degeneration is the major cause of legal blindness in Europe and the USA in patients aged more than 65 years, but Chakravarthy et al. has reported that radiotherapy has a beneficial effect on visual acuity. Methods: Since March 1996 we have treated 56 patients in cooperation with the Department of Radiotherapy at the Technical University in Munich. The total dose with external beam radiotherapy was 16 Gy in 8 fractions, delivered through an anterior oblique axis to spare the lens. Before the treatment and 3, 6 and 12 months after therapy, we performed a standardized visual acuity and contrast-sensitivity test (ETDRS, Pelli Robson Chard) and fluorescin angiography 6 and 12 months after therapy. Results: Twenty-five angiograms showed well-defined CNV and 31 not well-defined CNV. Six months after the treatment 15 patients had stable visual acuity within one line. Twenty-seven patients had lost more than one line of visual acuity. There was no difference between well and not well defined CNV's. One year after treatment the visual acuity remained stable within one line in 4 patients, no patient had an increase of two lines or more and 17 patients lost more then 2 lines of vision. We saw no side effects other than sicca symptoms in 3 patients. Conclusion: In our opinion, these results do not show that radiation treatment has a real beneficial effect on visual acuity. Further randomized studies are needed to demonstrate the efficiency of this treatment for choroidal neovascularization in AMD.      

Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration

PURPOSE: To describe transient structured visual hallucinations in a patient with vascular age-related macular degeneration (AMD), following an intravitreal Avastin-injection. DESIGN: Interventional case reports. METHODS: A fully alert 83-year-old woman with disciform scar right eye (OD) and occult choroidal neovascularization (CNV) left eye (OS) experienced a progressive visual loss to 20/800 OD and 20/400 OS. A coherent 84-year-old woman with occult CNV both eyes (OU) experienced decreased vision of 20/800 OU. After both patients gave informed consent, an uneventful intravitreal injection of 1.25 mg Avastin was performed in the left eyes. RESULTS: One day and three days after an uneventful intravitreal injection both patients experienced structured hallucinations including trees, faces, and water for approximately 15 to 30 minutes. CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections. The reduced retinal edema and realignment of the photoreceptors may promote the release phenomenon and trigger hallucinatory episodes.     

氩激光联合血栓通治疗老年黄斑变性58例

目的探讨老年黄斑变性(age—related macular degeneration,AMD)的有效治疗方法。方法根据AMD的诊断标准进行分型,并作相应的视力、视野、眼压、眼底镜、三面镜及眼底荧光造影检查。本文的研究对象主要是老年黄斑变性的渗出型,对病灶区有渗出、出血及新生血管膜者先使用氩激光进行光凝治疗,同时静脉点滴血栓通针剂2—3疗程,然后改为口服血栓通胶囊,6月为1疗程,可坚持长年用药。结果58例渗出型AMD中有效为49例(85％)。随访18～60(平均30±6)月,病情稳定44例(76％)。结论氩激光联合血栓通治疗AMD是一种较为有效的方法。